Join the Eliquis group to help and get support from people like you.
Eliquis News
ASA: No Drop in Recurrent Stroke Seen With Apixaban After Cryptogenic Stroke
FRIDAY, Feb. 16, 2024 – For patients with recent cryptogenic stroke and evidence of atrial cardiopathy, the risk for recurrent stroke is not reduced with apixaban versus aspirin, according to a...
Bleeding Higher With Standard-Dose DOACs in Nonvalvular A-Fib
THURSDAY, Nov. 16, 2023 – For nursing home residents with nonvalvular atrial fibrillation, the rate of bleeding is higher with standard- versus reduced-dose direct acting oral anticoagulants...
AHA: Apixaban Beneficial for Patients With Subclinical A-Fib
TUESDAY, Nov. 14, 2023 – Apixaban results in a lower risk for stroke or systemic embolism than aspirin for patients with subclinical atrial fibrillation, according to a study published online Nov....
Major Drug Companies Agree to Price Negotiations With U.S. Government
TUESDAY, Oct. 3, 2023 – Pharmaceutical companies that make the 10 prescription drugs chosen to be the first for price negotiations for Medicare patients have agreed to talks with the government. The...
Apixaban Has Lower Bleeding Risk for Initial Anticoagulation for Venous Thromboembolism
TUESDAY, Sept. 5, 2023 – Apixaban has a lower bleeding risk than warfarin or rivaroxaban during initial treatment for patients with venous thromboembolism (VTE), according to a study published...
FDA Approves Portola Pharmaceuticals’ Andexxa, First and Only Antidote for the Reversal of Factor Xa Inhibitors
SOUTH SAN FRANCISCO, Calif., May 03, 2018 (GLOBE NEWSWIRE) – Portola Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Andexxa [coagulation factor...
FDA Medwatch Alert: Eliquis (apixaban) 5 mg tablets: Recall One Lot- Bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets
ISSUE: Bristol-Myers Squibb Company is voluntarily recalling one lot (#HN0063) of Eliquis 5 mg tablets to the consumer level. This lot was distributed nationwide in the U.S. to wholesalers and retail...
FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Thursday, August 21, 2014 - Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug...
FDA Approves Eliquis to Reduce Risk of Blood Clots Following Hip Or Knee Replacement Surgery
PRINCETON, N.J. & NEW YORK-- Friday, March 14, 2014 (BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Deep Vein Thrombosis (DVT), Deep Vein Thrombosis, Deep Vein Thrombosis - Prophylaxis, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Prevention of Thromboembolism in Atrial Fibrillation, Pulmonary Embolism, Thromboembolic Stroke Prophylaxis